



Year: 2022

Representativeness of Systemic Sclerosis Patients in Interventional Randomized Trials: an analysis of the EUSTAR database

Iudici, Michele ; Jarlborg, Matthias ; Lauper, Kim ; Müller-Ladner, Ulf ; Smith, Vanessa ; Allanore, Yannick ; Balbir-Gurman, Alexandra ; Doria, Andrea ; Airò, Paolo ; Walker, Ulrich A ; Riccieri, Valeria ; Vonk, Madelon C ; Gabrielli, Armando ; Hoffmann-Vold, Anna-Maria ; Szücs, Gabriella ; Martin, Thierry ; Distler, Oliver ; Courvoisier, Delphine S ; EUSTAR collaborators

Abstract: **OBJECTIVE:** To estimate the extent of and the reasons for ineligibility in randomized controlled trials (RCTs) of systemic sclerosis (SSc) patients included in the EUSTAR database, and to determine the association between patient's features and generalizability of study results. **METHODS:** We searched Clinicaltrials.gov for all records on interventional SSc-RCTs registered from January 2013 to January 2018. Two reviewers selected studies, and information on the main trial features were retrieved. Data from 8046 patients having a visit in the EUSTAR database since 2013 were used to check patient's eligibility. The proportion of potentially eligible patients per trial, and the risk factors for ineligibility were analyzed. Complete-, worst- and best-case analyses were performed. **RESULTS:** Of the 37 RCTs included, 43% were conducted in Europe, 35% were industry-funded, and 87% investigated pharmacological treatments. Ninety-one percent of 8046 patients included could have participated in at least one RCT. In complete-case analysis, the median [range] proportion of eligible patients having the main organ complication targeted by each study was 60% [10-100] in the overall sample of trials, ranging from 50% [32-79] for trials on skin fibrosis to 90% [34-77] for those targeting Raynaud's phenomenon. Among the criteria checked, treatment- and safety-related but not demographic were the main barriers to patient's recruitment. Older age, absence of Raynaud's phenomenon, and lower mRSS were independently associated with the failure to fulfill criteria for any of the included studies. **CONCLUSIONS:** Patient's representativeness in SSc-RCTs is highly variable and is driven more by treatment- and safety-related rather than demographic criteria.

DOI: <https://doi.org/10.1093/rheumatology/keab437>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-203491>

Journal Article

Accepted Version

Originally published at:

Iudici, Michele; Jarlborg, Matthias; Lauper, Kim; Müller-Ladner, Ulf; Smith, Vanessa; Allanore, Yannick; Balbir-Gurman, Alexandra; Doria, Andrea; Airò, Paolo; Walker, Ulrich A; Riccieri, Valeria; Vonk, Madelon C; Gabrielli, Armando; Hoffmann-Vold, Anna-Maria; Szücs, Gabriella; Martin, Thierry; Distler, Oliver; Courvoisier, Delphine S; EUSTAR collaborators (2022). Representativeness of Systemic Sclerosis Patients in Interventional Randomized Trials: an analysis of the EUSTAR database. *Rheumatology*, 61(2):743-755.

DOI: <https://doi.org/10.1093/rheumatology/keab437>

Representativeness of Systemic Sclerosis Patients in Interventional Randomized Trials: an analysis of the EUSTAR database.

Michele Iudici¹, Matthias Jarlborg¹, Kim Lauper¹, Ulf Müller-Ladner², Vanessa Smith^{3,4}, Yannick Allanore⁵, Alexandra Balbir-Gurman⁶, Andrea Doria⁷, Paolo Airò⁸, Ulrich A. Walker⁹, Valeria Ricciari¹⁰, Madelon C Vonk¹¹, Armando Gabrielli¹², Anna-Maria Hoffmann-Vold¹³, Gabriella Szücs¹⁴, Thierry Martin¹⁵, Oliver Distler¹⁶, Delphine S Courvoisier¹; and EUSTAR collaborators*.

Affiliations

¹ Rheumatology Unit, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.

² Justus-Liebig-University of Giessen, Campus Kerckhoff, Bad Nauheim, Germany.

³ Department of Internal Medicine, Ghent University, Ghent, Belgium.

⁴ Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium.

⁵ Service de Rhumatologie, Cochin Hospital, APHP, Paris Descartes University, Paris, France.

⁶ B Shine Rheumatology Institute, Rambam Health Care Campus, Haifa, Israel.

⁷ Department of Rheumatology, University of Padova, Padova, Italy.

⁸ Rheumatology and Clinical Immunology, Spedali Civili, Brescia, Italy.

⁹ Department of Rheumatology, University Hospital Basel, Basel, Switzerland.

¹⁰ Dipartimento di Scienze Cliniche Internistiche Anestesiologiche e Cardiovascolari, Sapienza University of Rome, Rome, Italy.

¹¹ Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands.

¹² Clinica Medica, Ospedali Riuniti di Ancona, Ancona, Italy.

¹³ Department of Rheumatology, Oslo University Hospital, Oslo, Norway.

¹⁴ Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

¹⁵ Clinical immunology department, Hôpitaux Universitaires de Strasbourg, Centre National de Référence des Maladies Systémiques et Auto-immunes Rares Grand-Est Sud-Ouest (RESO), Strasbourg, France.

¹⁶ Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

*EUSTAR collaborators are listed at the end of the manuscript

Corresponding author:

Michele Iudici, MD, PhD, Division of Rheumatology, Department of Medicine, Geneva University Hospitals, Switzerland.

email. michele.iudici@hcuge.ch

Word count: 2998; 5 Tables, 1 Figure.

Keywords: systemic sclerosis, randomized controlled trial, epidemiology.

Key messages

- A poor representativeness of real-life patients in clinical trials is a major factor limiting the generalizability of study results.
- Patient’s representativeness in SSc-RCTs is highly variable across studies.
- Older age, absence of Raynaud’s phenomenon, and lower mRSS are risk factors for SSc-RCTs ineligibility.

Funding. No specific funding was received from any funding bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript.

Competing interests. YA received consulting fees from Boehringer, Sanofi, Medsenic, Menarini, Topadur in the area of the treatment of systemic sclerosis. AMHV has received research funding and/or consulting fees and/or other remuneration from Actelion, Boehringer Ingelheim, Roche, Bayer, Merck Sharp & Dohme, ARXX, Lilly and Medscape. PA reports consultancy or non-financial support from Bristol Myers Squibb, Bohringer Ingelheim, CSL Behring, SOBI, Janssen, Roche, Sanofi, (each: < 3,000 Euro) outside the submitted work. OD has/had consultancy relationship with and/or has received research funding from or has served as a speaker for the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three years: Abbvie, Acceleron, Amgen, AnaMar, Arxx, Baecon, Blade, Bayer, Boehringer Ingelheim, ChemomAb, Corbus, CSL Behring, Galapagos NV, Glenmark, GSK, Horizon (Curzion), Inventiva, iQvia, Italfarmaco, Kymera, Medac, Medscape, Mitsubishi Tanabe, MSD, Novartis, Pfizer, Roche, Roivant, Sanofi, Serodapharm, Topadur, Target Bioscience and UCB. Patent issued “mir-29 for the treatment of systemic sclerosis” (US8247389, EP2331143). Iudici, Jarlborg, Lauper, Müller-Ladner, Smith, Balbir-Gurman, Doria, Walker, Riccieri, Vonk, Gabrielli, Szücs, Martin, Courvoisier have no conflicts of interest.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective. To estimate the extent of and the reasons for ineligibility in randomized controlled trials (RCTs) of systemic sclerosis (SSc) patients included in the EUSTAR database, and to determine the association between patient’s features and generalizability of study results.

Methods. We searched Clinicaltrials.gov for all records on interventional SSc-RCTs registered from January 2013 to January 2018. Two reviewers selected studies, and information on the main trial features were retrieved. Data from 8046 patients having a visit in the EUSTAR database since 2013 were used to check patient’s eligibility. The proportion of potentially eligible patients per trial, and the risk factors for ineligibility were analyzed. Complete-, worst- and best-case analyses were performed.

Results. Of the 37 RCTs included, 43% were conducted in Europe, 35% were industry-funded, and 87% investigated pharmacological treatments. Ninety-one percent of 8046 patients included could have participated in at least one RCT. In complete-case analysis, the median [range] proportion of eligible patients having the main organ complication targeted by each study was 60% [10-100] in the overall sample of trials, ranging from 50% [32-79] for trials on skin fibrosis to 90% [34-77] for those targeting Raynaud’s phenomenon. Among the criteria checked, treatment- and safety-related but not demographic were the main barriers to patient’s recruitment. Older age, absence of Raynaud’s phenomenon, and lower mRSS were independently associated with the failure to fulfill criteria for any of the included studies.

Conclusions. Patient’s representativeness in SSc-RCTs is highly variable and is driven more by treatment- and safety-related rather than demographic criteria.

Introduction

Systemic sclerosis (SSc) is a rare, systemic autoimmune disease characterized by vasculopathy, dysregulation of the immune system and fibrosis (1). Due to the rarity of the disease, the heterogeneity of clinical phenotypes (2), and the difficulty to develop reliable outcome measures, conducting research in SSc is challenging (3,4).

Randomized controlled trials (RCTs) are the gold standard to estimate the efficacy of medical interventions (5), and are conducted under rigorous conditions. Aside from patient randomization, the assessment of adherence to protocol, the use of validated statistical methods, and the careful choice of eligibility criteria are necessary to minimize the occurrence of bias and to produce reliable results within the sample of individuals participating in the study (internal validity)(6). However, if the recruited subjects are not sufficiently similar in clinically relevant characteristics to those seen in daily practice, the applicability of study results to a target population can be impaired (7,8). This means that individuals underrepresented in trials could be prevented from receiving the benefits of a new drug or, conversely, be exposed to unexpected harms. The extensive use of unnecessary, and too restrictive eligibility criteria, is the main driver of poor generalizability of RCTs results (9). This issue has been shown to be common across different medical specialties, but few data are available for SSc (10). The only study in SSc, published more than 10 years ago (11), found that only a minority of SSc patients could have been suitable to enter in RCTs, but reasons of such low eligibility rate were not investigated. Considering the importance of ensuring the highest number of SSc patients to be potentially enrolled and therefore benefit from interventions investigated in clinical trials, we planned this

study: to estimate to what extent SSc patients enrolled in the EUSTAR database could have participated in RCTs conducted over 5 years; to determine patient's characteristics associated with RCT non-eligibility; and to analyze geographical differences in patient's eligibility.

Methods

Search, data collection and definition of eligibility criteria in registered RCTs

On 28 February 2018, we searched on Clinicaltrials.gov (12) all records of interventional SSc-RCTs registered from January 2013 through January 2018. We used the terms 'systemic sclerosis' OR 'scleroderma' OR 'SSc'. We defined as interventional a study in which participants are assigned to groups receiving therapeutic intervention/treatment as determined by protocol. We excluded fundamental research, diagnostic and cost-effectiveness studies, and RCTs for which the EUSTAR database lacked the items needed to identify the main condition investigated (e.g. sleep disorders). Two reviewers (MI, MJ) independently checked the studies against the pre-specified criteria and extracted data by using a standardized form. The complete list is in online file. For both tasks, consensus was reached by discussion. A third reviewer was available in case of unresolved disagreement. The following study characteristics were collected: country, funding, phase of development, planned sample size, type of intervention, type of comparator (placebo, active intervention, usual care, or no intervention). A study was considered being industry-funded if the sponsor, as defined in the glossary of ClinicalTrials.gov (12), was industry. Eligibility criteria were extracted for each study. Exclusion criteria were reformulated to obtain the correspondent inclusion criteria. For example, a criterion excluding patients with a serum creatinine >2.0 mg/dl, was rephrased in an equivalent criterion including patients with a creatinine ≤2.0 mg/dl. Then, each criterion was classified in one of the

1
2
3 following categories: *characteristics of the disease*: defining clinical parameters of the
4 disease being studied; *treatment*: concerning future, previous or current drug intake,
5 or surgery; *safety*: organ function, laboratory test and co-morbidity requests that
6 ensure the safety of the participants to enter the trial; *demographic criteria*: related to
7 age, sex, ethnicity; *ethical and administrative*: attempting to ensure conformity with
8 legal and ethical norms of human experimentation and functioning of the study (9).
9
10 Trials were grouped according to the SSc organ manifestation investigated (skin
11 fibrosis, interstitial lung disease [ILD], digital ulcers, Raynaud's phenomenon (RP),
12 gastrointestinal tract, pulmonary hypertension, kidney) (13). Creatinine clearance was
13 obtained from serum creatinine values by Cockcroft-Gault formula (14).
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 ***Data analysis: description of EUSTAR database and trial eligibility***
29 ***assessment in target population***
30
31

32 The structure of the EUSTAR database and minimum essential dataset have been
33 described previously (15, 16). Local ethic committee permission for each EUSTAR
34 center, and patient written informed consent were obtained prior to EUSTAR
35 enrolment, as required according to national law (approval from the CCER –
36 Commission cantonale d'éthique de la recherche - number 09/022 for Geneva
37 University Hospitals). Trial eligibility was checked for SSc patients having at least one
38 visit in database since 2013. We restricted the study to patient's visits recorded after
39 2013 to evaluate representativeness in the same time span trials would have been
40 potentially conducted. Number of eligibility criteria with no information in EUSTAR
41 within each category (e.g. ethics) were collected, reported for each study, and
42 considered to be always fulfilled. Criteria requiring the discontinuation of one or more
43 drugs or having a stable dose before enrolment, were also considered always fulfilled.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 For each trial, we calculated the proportion of potentially eligible patients (i.e. fulfilling

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

all criteria at each given visit after 2013) for those with no missing data (complete-case analysis). We then adjusted for missing data by performing a sensitivity analysis imputing criterion as not fulfilled (worst-case scenario) or fulfilled (best-case scenario). We then conducted subgroup analyses to identify the rate of (in)eligibility a) among those fulfilling for each trial the ‘disease characteristics’ criteria (e.g., patients with digital ulcers for trials on digital ulcers), to provide an estimate of representativeness in the sample of patients to whom the intervention would have been delivered; and b) only in countries enrolling at least 100 patients. Reasons for ineligibility were reported. The main features of patients who resulted to be always ineligible (‘never eligible’) in overall sample of studies and within each category of trial vs. those eligible in at least one RCT (‘ever eligible’) were compared.

Data analysis

Analyses were performed using R 3.3.2. statistical software (R Development Core Team, Vienna, Austria). For categorical variables, data were presented as frequencies and percentages. Continuous variables were expressed as median [interquartile range]. Factors associated with trial ineligibility in all studies, and in subgroups of RCTs grouping more than 3 studies (skin fibrosis, ILD, RP) were identified by univariable and multivariable logistic regression model.

Results

Characteristics of patients enrolled in EUSTAR database

In total, 8046 patients, 1193 (15%) males, 31% dcSSc, with a median age and disease duration from the onset of first non-Raynaud’s symptom of 58 (IQR 48-67) years, and

9 (IQR 4-15) years respectively, were studied. Main characteristics of patients at first available visit are summarized in Table 1.

General characteristics of trials

Among the 37 RCTs included (figure S1 in online file), 43% were conducted in Europe, 35% were industry-funded, 86% investigated pharmacological treatments, with placebo as comparator in most of them (78%). Most RCTs evaluated treatments given for skin fibrosis or RP/digital ulcers. Table 2 shows the main features of the included studies.

Overall, we retrieved from Clinicaltrials.gov 575 eligibility criteria, distributed in the following categories: 46% safety; 29% characteristics of disease; 14% treatment; 7% ethical and administrative; 4% demographic. With the data available in EUSTAR database, we were able to check the fulfilment of 100% of demographic criteria (n=24/24); 90% of disease characteristics criteria (n=154/170); 58% of treatment-related criteria (n=47/81); 26% (n=68/262) of safety-related; and no ethics or administrative criteria.

Estimation of eligibility

The proportion of patients who could have entered in at least one RCT was 91% (n=7323) for all studies; 33% (n=2697), 24% (n=1933), 85% (n=6807), and 19% (n=1540) in the subgroups of studies on skin fibrosis, ILD, RP, and digital ulcers, respectively.

The median proportion of eligible patients per trial (in overall and within each trial category) varied greatly, being 11% [0.2-92] for the overall sample of studies; 7% [0.2-62] for all the studies on skin fibrosis, 17% [11- 62] for studies on skin fibrosis recruiting

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

both lcSSc and dcSSc (n=4), 4% [0.2-11] for those including only dcSSc (n=11); 10% [1.5-42] for studies on ILD (n=5); 48% [14-92] for studies on RP (n=7); and 21% [2-24] for those on digital ulcers (n=3) (complete-case analysis) (Table 3). When we restricted the analysis to patients with the condition targeted by the trial, the median [range] proportion of eligible patients increased to 60% [10-100] in the overall sample of trials, ranging from 50% [32-79] for trials on skin fibrosis to 89% [34-77] for those targeting RP (complete-case analysis). The estimates of eligibility per trial in complete-, worst- and best-case analysis, are reported in Table 3.

Barriers to recruitment and patient’s characteristics associated with lack of eligibility

The analysis restricted to patients with the condition of interest for each study showed that demographic criteria were satisfied by >95% of patients in 87% of studies, while the fulfilment of treatment- and safety-related (>95% of patients in 48% and 53% of RCTs, respectively) criteria was lower.

Comparisons of main features of ‘never’ vs. ‘ever’ eligible patients in the whole sample or within each category of studies are provided in online file (complete-case).

Table 4 shows the main patient’s demographic and disease-related features associated with the status of ‘never eligible’, in the whole sample and within each trial category considered (see also Tables S1-S5 in online file). The proportion of ‘never eligible’ patients was quite homogeneous across centers according to their academic status (Figure S2), and their size (with a higher variability among those recruiting less than 100 patients) (Figure S3). Patients recruited by Internal Medicine centers were more often eligible for none of the RCT compared to other recruiting specialties centers (Figure S4).

Older patients, with a lower modified Rodnan skin score (mRSS), and with no current RP had the lowest chance to be recruited in any of the trials included in the analysis. For RCTs on skin fibrosis, main patient's characteristics independently associated with the lack of criteria fulfilment were older age, longer disease duration, lcSSc subset, low mRSS, and the co-existence of pulmonary hypertension. For RCTs on ILD, older age, creatine kinase elevation and anti-centromere antibodies positivity increased the risk of ineligibility. Anti-Scl-70 positive patients were more likely to be eligible in studies on skin fibrosis and ILD (Table 4).

Geographical differences in patient's eligibility

Trial ineligibility was heterogeneous across countries (Figure 1 and Table 5). For RP studies, the rates of 'never eligible' patients were very low in some countries, like UK (1.4%), Hungary (1.4%), and Russia (3.5%), with the highest figure in Croatia (44.8%). Apart from a few exceptions (Denmark, Israel, Romania, Russia), the proportion of 'never eligible' patients for trials on digital ulcers was homogeneously above the 75%. More heterogeneous was the proportion of patients across countries who could have never entered in skin fibrosis (from 40% in Romania to 86% in Denmark), or ILD (from 27% in Russia to 96% in Israel) trials. No difference in never eligibility rates was found among those countries for which a definition of Welfare regimen was available (17)(details in online file, Figure S5).

Discussion

We aimed to estimate the extent of and the reasons for ineligibility in RCTs enrolling SSc patients over a 5-year period, and to determine factors associated with trial generalizability of study results.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

We have found that the representativeness of real-world SSc patients in RCTs is highly variable across studies, and is driven more by treatment- and safety-related rather than demographic criteria, within those available in the database. The extent to which SSc patients could have entered trials varied according to how patient’s representativeness has been estimated, and to the different complications addressed by the studies. Globally, in a first analysis conducted on the overall sample, one of ten patients resulted to be eligible on average in each study, with figures different according to the organ manifestations assessed by the trials. We found, for example, that about half and less than one tenth of patients could have been recruited in studies on RP or in those on skin fibrosis or ILD, respectively. This finding, undoubtedly influenced by the different prevalence of each SSc organ manifestation, is quite similar to that detected by the only paper on the topic conducted more than 10 years ago, and can erroneously lead to conclude that the representativeness of SSc patients in RCTs is very poor (11). In fact, in their paper Villela et al emphasized the very high rate of patients deemed RCT ineligible, with the subsequent issues of poor generalizability of study results (11). To overcome the limitation of such approach, we have also estimated the theoretical eligibility rate within the subgroup of patients for whom interventions were intended to be potentially delivered, i.e. the eligibility of patients with digital ulcers for trials targeting this condition. In this second analysis, the median proportion of patients suitable to fulfill criteria for trials was higher (about 60%) as expected, with still some differences observed among the different trial groups, ranging from 50% in studies targeting the skin fibrosis to about 90% for those on RP. This observation firstly mitigates the concern about a very poor generalizability of SSc-RCTs (11), but also underlines that, even ‘adjusting’ for the condition of interest, the representativeness of patients in SSc-RCTs even in our optimistic estimate is not ‘perfect’ yet. Second, the observed lower

inclusiveness in RCTs on skin fibrosis and ILD if compared to that recorded in digital ulcers or RP, would suggest that more stringent criteria, notably treatment- or safety-related, regulate the access in the former group of studies. We can hypothesize that this could represent the obvious consequence of the higher potential safety concerns associated with the use of drugs given for these indications (mostly immunomodulatory drugs), versus those conceived for RP or digital ulcers (mostly vasodilators) (15).

However, whether having a 'perfect' patient's representativeness in RCTs is a realistic and feasible objective, and what should be the ideal cut-off to achieve to consider a study 'representative enough' of patients seen in routine care, is hard to state. In fact, also in daily practice, we choose not to deliver a given treatment for various reasons, such as the absence of an active disease (as patient enrichment in RCTs), or for the co-existence of comorbidities which contraindicate its use or to avoid dangerous drug interactions.

Therefore, establishing if and to what extent the choice of each exclusion criterion could have been reasonably justified on a clinical basis, or conversely mirrors the exaggerated need to minimize the occurrence of drop outs or adverse events, represents a difficult challenge.

The availability of an international database and a large set of eligibility criteria has also allowed us to better depict the features of patients less likely to enter in trials and therefore excluded from the potential benefit coming from the interventions tested, or more exposed to their unwanted harms. On average, older patients, those with a less severe extent of skin fibrosis, and without an active RP fall within this group. The underrepresentation of older patients in SSc-RCTs, even though demographic criteria were not identified as a main barrier to patient's enrolment, suggests that the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

combination of factors other than demographic criteria such as comorbidities, exposure to previous treatment, or other safety issues, limit the access to trials to the elderly. Our finding is in line with reports from other specialties (18, 19) and highlights the need to increase the efforts to improve the recruitment also for these more vulnerable and frail patients in our growing older population (20). Post-approval registries can also contribute to fill this gap by helping to evaluate in routine care the risk/benefit ratio of treating the previously unexposed and vulnerable patients (21).

Our data confirms the need to expand the core of studies for patients with lcSSc. We found that lcSSc subset, milder skin involvement, or anti-centromere positivity for studies on ILD, independently impaired the odds to take part in trials and therefore to potentially receive a tested treatment in the real-world. This observed lower inclusiveness of lcSSc patients reflects the numeric imbalance in favor of trials designed for the dcSSc subset. In this regard, it has been recently shown that 25% of RCTs registered between years 2007-2018 were not intended to be delivered to lcSSc patients (3). Furthermore, the paucity of studies addressing frequent and disabling complications seen in this subset of patients like calcinosis, gastroesophageal or intestinal impairment or the physical and facial consequences of SSc, further corroborates our observation. The lower number of studies for lcSSc, despite being the more frequent subset, mirrors the difficulties of designing RCTs for these patients. The heterogeneity of the phenotype, the varied course, ranging from a quiescent or slow progressing disease, the absence of validated outcome measures for some organ involvement, are, among others, the main barriers to conduct trials in lcSSc patients. The development of outcome measures for lcSSc patients is the object of an ongoing study (22).

The analysis of the geographical differences in patient's eligibility shows that apart from a few exceptions, the fulfillment of criteria for trials on digital ulcers was quite homogeneous, while more discrepant data were recorded in the other categories. Capturing the real reasons underlying this finding remains a challenge since eligibility was similar across health care systems, size of recruiting centers, and academic status. Some difference was seen between internal medicine centers compared to specialties centers. Nevertheless, as a descriptive analysis, this information is useful to plan recruitment ability and estimate feasibility of clinical trial.

Some study limitations should be acknowledged. Since we imputed as fulfilled unavailable criteria in EUSTAR, our results represent an optimistic estimation of trial eligibility. Moreover, our analysis did not incorporate all the trials registered in the period considered, since we could not include RCTs intended to investigate aspects for which we had no information in the database (e.g. sleep problems). Study conclusions should therefore be interpreted considering this aspect. Furthermore, the identification of the subgroups of patients for whom interventions were planned, was based on the fulfillment of the 'Characteristics of the disease' criteria since there is not a unique definition for each SSc given complication (i.e. many different possible definitions for ILD). This could have further led to an optimistic estimation of patient's eligibility. Limitations of the analysis on geographical differences in patient inclusiveness should also be acknowledged. Potential reasons for this finding include: a real heterogeneity of SSc phenotypes in different geographical areas (23); differences how patients are recruited in centers/countries; the number of academic versus non-academic recruiting centers in each country.

This paper has several strengths. This study is the first conducted in a large, international sample of real-life patients, allowing more realistic estimates of

(in)eligibility rates by focusing on the subgroups of patients with the peculiar clinical manifestation targeted by the trial. The identification of the main barrier to study participation and the patient's features associated with, represents another novelty aspect and provides knowledge for future study design.

In conclusion, we have shown that the proportion of SSc patients allowed to participate in RCTs is highly variable across studies and that while being aware of the unavailability of certain factors commonly used to enrich cohorts and limiting patient's inclusiveness in trials, treatment-related and general safety issues represent relevant barriers to study participation. Despite the fact that demographic criteria permit the involvement of all patient ages, the elderly are still underrepresented in RCTs. Importantly the need of patients with lcSSc subset is still unmet. A better understanding and awareness of barriers to patient recruitment when designing SSc-RCTs may improve generalizability of results and favour the translation of RCTs efficacy results to real-world patients.

Acknowledgements. None

Data availability statement. The data that support the findings of this study are available upon reasonable request.

Author contributions.

Conception and design. Iudici, Courvoisier. **Acquisition of data.** Iudici, Jarlborg, Lauper, Müller-Ladner, Smith, Allanore, Balbir-Gurman, Doria, Airò, Walker, Riccieri, Vonk, Gabrielli, Szücs, Martin, Distler. **Analysis and/or interpretation of data.** Iudici, Jarlborg, Lauper, Müller-Ladner, Smith, Allanore, Balbir-Gurman, Doria, Airò, Walker,

Ricceri, Vonk, Gabrielli, Hoffmann-Vold, Szücs, Martin, Distler, Courvoisier. **Draft of the manuscript and critical revision of the paper for intellectual content.** Iudici, Jarlborg, Lauper, Müller-Ladner, Smith, Allanore, Balbir-Gurman, Doria, Airò, Walker, Ricceri, Vonk, Gabrielli, Hoffmann-Vold, Szücs, Martin, Distler, Courvoisier.

EUSTAR collaborators (in ascending centre order):

Marco Matucci-Cerinic (Dept of Medicine, Section of Rheumatology, University of Florence, Florence, Italy); Veronika Jaeger (Unispital Basel, Department of Rheumatology, Basel, Switzerland); Florenzo Iannone (Rheumatology Unit- DiMIMP, School of Medicine University of Bari, Italy); Britta Maurer (Department of Rheumatology, University Hospital Zurich, Gloriastr, 25 CH-8032, Zürich, Switzerland); Radim Becvar (Institute of Rheumatology and Department of Rheumatology, 1st Medical School, Charles University, Prague, Czech Republic); Maurizio Cutolo, Carmen Pizzorni (Research Laboratory and Division of Rheumatology Department of Internal Medicine, University of Genova, Viale Benedetto XV, 6 I-16132); Gabriele Valentini (Dipartimento Medicina Clinica e Sperimentale "F-Magrassi" Il Policlinico U.O. Reumatologia, Via Pansini, 5, I-80131 Napoli, Italy); Elise Siegert (Department of Rheumatology, Charité University Hospital Charité Platz 1 D-10117 Berlin, Germany); Simona Rednic (Rheumatology Clinic, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania); Jérôme Avouac (Rheumatology A dpt, Paris 5 University Cochin Hospital, 27 rue Faubourg Saint-Jacques 75014 Paris, France); Panayiotis Vlachoyiannopoulos (Department of Pathophysiology Medical School, National University of Athens, 75 M. Asias str, Goudi 11527 Athens, Greece); Carlomaurizio Montecucco (Unità Operativa e Cattedra di Reumatologia, IRCCS Policlinico S Matteo, Pavia, Italy); Patricia Carreira (Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid, Spain); Srdan Novak (Dep. of

Rheumatology and Clinical Immunology, Internal medicine KBC Rijeka, Croatia); László Cziráj (Department of Rheumatology and Immunology, Medical Centre, University of Pécs, Pécs, Hungary); Eugene J. Kucharz (Department of Internal Medicine and Rheumatology Medical University of Silesia ul. Ziolowa 45/47 PL 40-634 Katowice, Poland); Elisabetta Zanatta (Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Via Giustiniani, 2 I-35128 Padova, Italy); Bernard Coleiro ("Stella Maris" 7 Kannizzata Street, Balzan BZN 07-Malta); Gianluca Moroncini (Istituto di Clinica Medica, Università Politecnica delle Marche Polo Didattico University of Ancona, Ancona, Italy); Dominique Farge Bancel (Department of Internal Medicine, Hopital Saint-Louis 1, Avenue Claude Vellefaux 75010 Paris, France); Maria-Grazia Lazzaroni (Spedali Civili di Brescia, Servizio di Reumatologia Allergologia e Immunologia Clinica, Brescia, Italy); Roger Hesselstrand (Department of Rheumatology, Lund University Hospital S-22185 Lund, Sweden); Mislav Radić (Department of Internal Clinic. Clinical Hospital of Split, Split, Croatia); Yolanda Braun-Moscovici (B. Shine Rheumatology Unit, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel); Nicolas Hunzelmann (Universitätsklinik Köln, Köln, Germany); Raffaele Pellerito (Ospedale Mauriziano, Centro di Reumatologia, Largo Turati 62 10128 Torino, Italy); Alessandro Giollo (Università degli Studi di Verona, Dipartimento di Medicina Clinica e Sperimentale, Rheumatology Unit, Policlinico GB Rossi, Verona, Italy); Jadranka Morovic-Vergles (Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Dubrava University Hospital, Zagreb, Croatia); Christopher Denton (Centre for Rheumatology, Royal Free and University College London Medical School, London, United Kingdom); Nemanja Damjanov (Institute of Rheumatology Belgrade Resavska 69 11000 Belgrade, Serbia & Montenegro); Jörg Henes (Medizinische

1
2
3 Universitätsklinik Abt. II - Onkologie, Hämatologie, Rheumatologie Immunologie,
4 Pulmonologie - Otfried-Müller-Strasse 10 D-72076 Tübingen, Germany); Vera Ortiz
5
6 Santamaria (Rheumatology Granollers General Hospital, Barcelona, Spain); Stefan
7
8 Heitmann (Department of Rheumatology, Marienhospital Stuttgart, Stuttgart,
9
10 Germany); Dorota Krasowska (Department of Dermatology, Venereology and
11
12 Pediatric Dermatology, Medical University of Lublin, Lublin, Poland); Paul Hasler
13
14 (Kantonsspital Aarau, Rheumaklinik und Institut für Physikalische Medizin und
15
16 Rehabilitation Kantonsspital Aarau Tellstrasse 5001 Aarau, Switzerland); Michaela
17
18 Kohm (Klinikum der Johann Wolfgang Goethe Universität Medizinische Klinik III,
19
20 Rheumatologische Ambulanz Theodor-Stern-Kai 7 D- Frankfurt am Main, Germany);
21
22 Ivan Foeldvari (Hamburger Zentrum für Kinder- und Jugendrheumatologie
23
24 Kompetenz-Zentrum für Uveitis und Sklerodermie im Kindes- und Jugendalter An der
25
26 Schön Klinik Hamburg Eilbek, Haus 8, Anmeldung Raum 215, II. Stock Dehnhaide
27
28 120 22081 Hamburg, Germany); Maria João Salvador (Rheumatology Department,
29
30 Hospitais da Universidade 3000-075 Coimbra, Portugal); Bojana Stamenkovic
31
32 (Institute for prevention, treatment and rehabilitation rheumatic and cardiovascular
33
34 disease, Niska Banja, Serbia and Montenegro); Carlo Francesco Selmi (Division of
35
36 Rheumatology and Clinical Immunology Humanitas Clinical and Research Center
37
38 BIOMETRA Department, University of Milan, Italy Via Manzoni 56, 20089 Rozzano,
39
40 Milano, Italy); Lidia Ananieva (Laboratory of microcirculation and inflammation, VA
41
42 Nasonova Institute of Rheumatology, Moscow, Russian Federation); Ariane Herrick
43
44 (Salford Royal Hospital - University of Manchester, Salford, United Kingdom); Merete
45
46 Engelhart (Department of Rheumatology, University Hospital of Gentofte, Hellerup,
47
48 Denmark); Szilvia Szamosi (Third Department of Medicine, Rheumatology Division
49
50 University of Debrecen, Medical Center 22 Moricz street H-4004 Debrecen, Hungary);
51
52
53
54
55
56
57
58
59
60

Carlos De La Puente (Servicio de Reumatología, Hospital Ramon Y Cajal, Madrid, Spain); Øyvind Midtvedt (Department of Rheumatology, Rikshospitalet University Hospital, Oslo, Norway); David Launay (Department of Internal Medicine and Clinical Immunology, Huriez Hospital, University of Lille, Lille, France); Massimiliano Vasile (Dipartimento di Medicina Interna e Specialità Mediche, "Sapienza" Università di Roma Viale del Policlinico 155 00161 Rome, Italy); Ruxandra Maria Ionescu (Department of Rheumatology - St. Maria Hospital, Carol Davila, University of Medicine and Pharmacy, Bucharest, Romania); Ana Maria Gheorghiu (Department of Rheumatology - Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania); Cord Sunderkötter (Department of Dermatology, University of Münster, Münster, Germany); Jörg Distler (Department of Internal Medicine 3, Universitätsklinikum Erlangen, Erlangen, Germany); Francesca Ingegnoli (Division of Rheumatology, Istituto Gaetano Pini, Department of Clinical Sciences & Community Health, University of Milano, Milano, Italy); Luc Mouthon (Department of Internal Medicine - Hôpital Cochin 27 rue du Faubourg Saint-Jacques 75014 Paris, France); Francesco Paolo Cantatore (U.O. Reumatologia-Università degli Studi di Foggia, Ospedale "Col. D'Avanzo" Viale degli Aviatori - 71100 Foggia, Italy); Susanne Ullman (University Hospital of Copenhagen, Department of Dermatology D-40, HS-Bispebjerg Hospital, Copenhagen); Maria Rosa Pozzi (Dipartimento di Medicina, Ospedale San Gerardo, Monza, Italy); Kilian Eyerich (Department of Dermatology and Allergy of the TU Munich, Munich, Germany); Piotr Wiland (Department of Rheumatology and Internal Diseases Wroclaw University of Medicine Ul. Borowska 213 50-556 Wroclaw, Poland); Marie Vanthuyne (Université Catholique de Louvain, Cliniques Universitaires St-Luc, Bruxelles, Belgium); Juan Jose Alegre-Sancho (Hospital Universitario Dr Peset Avda. Gaspar Aguilar, 90 46017 Valencia, Spain); Kristine Herrmann (Division of

Rheumatology, Department of Medicine II, University Medical Center Carl Gustav Carus, Technical University of Dresden, Dresden, Germany); Ellen De Langhe (Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium); Marko Baresic, Miroslav Mayer, Branimir Anic (Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Zagreb, School of Medicine, Zagreb, Croatia); Sule Yavuz (Istanbul Bilim University, Dept. of Rheumatology, Istanbul, Turkey); Brigitte Granel (Service de Médecine Interne, Hôpital Nord de Marseille, Marseille, France); Carolina de Souza Müller (Hospital de Clinicas da Universidade Federal do Parana Rua General Carneiro, 181 Curitiba - Parana – Brazil); Svetlana Agachi (Department of Rheumatology&Nephrology , SUMF "N. Testemitanu", Chisinau, Republic of Moldova); Simon Stebbings (Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin| PO Box 56, Dunedin, 9053, New Zealand); Alessandro Mathieu, Alessandra Vacca (II Chair of Rheumatology, University of Cagliari-Policlinico Universitario, Monserrato, Italy); Kamal Solanki (Waikato University Hospital, Rheumatology Unit, Hamilton City, New Zealand); Douglas Veale (Department of Rheumatology, Bone and Joint Unit, St. Vincent's University Hospital, Dublin, Ireland); Esthela Loyo, Carmen Tineo (Hospital Regional Universitario Jose Ma. Cabral y Baez, Santiago, Dominican Republic); Mengtao Li (Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 41 Da Mu Cang, Western District Beijing 100045, P.R. China); Edoardo Rosato (Sapienza Università di Roma, Dipartimento di Medicina Clinica, UOC di Medicina Interna e Nutrizione Clinica-Scleroderma Unit, Università La Sapienza, Policlinico Umberto I, Roma, Italy); Fahrettin Oksel, Figen Yagurcu (Ege University, Faculty of Medicine, Dept. of Internal Medicine, Division of Rheumatology, Izmir, Turkey); Cristina-Mihaela Tănăseanu (Clinical Emergency

Hospital St. Pantelimon, Bucharest, Romania); Rosario Foti (Rheumatology Unit; A.O.U. Policlinico V.E., Catania Italy); Codrina Ancuta (Clinical Rehabilitation Hospital, Rheumatology & Rehabilitation, 'Grigore T. Popa' University of Medicine and Pharmacy Iasi, Romania); Sabine Adler, Peter Villiger (Department of Rheumatology and Clinical Immunology/Allergology, Inselspital, University of Bern, Bern, Switzerland); Jacob van Laar (James Cook University Hospital Marton Road, Middlesbrough TS4 3BW, UK); Marzena Olesinska (Department of Connective Tissue Disease, Institute of Rheumatology, Spartanska 1 02-637 Warsaw, Poland); Cristiane Kayser (Universidade Federal de São Paulo - Disciplina de Reumatologia Rua Botucatu, 740 - 3. andar, São Paulo, SP, Brasil); Nihal Fathi (Assiut and Sohage University Hospital, Rheumatology Department Assiut University Hospital, Assiut, Egypt); Paloma García de la Peña Lefebvre, Jorge Juan González Martín (Hospital Universitario Madrid Norte Sanchinarro, Madrid, Spain); Jean Sibilia (University Hospital of Strasbourg-Department of Rheumatology, Hôpital de Hautepierre, Service de Rhumatologie, Strasbourg, France); Ira Litinsky (Rheumatology Institute, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel); Francesco Del Galdo (Scleroderma Programme, Institute of Molecular Medicine, Division of Musculoskeletal Diseases, University of Leeds, Chapel Allerton Hospital, Leeds, United Kingdom); Lesley Ann Sakettkoo (Tulane University Lung Center, Tulane / University Medical Center, Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, Louisiana, USA); Eduardo Kerzberg (Osteoarticular Diseases and Osteoporosis Centre, Pharmacology and Clinical Pharmacological Research Centre, School of medicine - University of Buenos Aires, Rheumatology and Collagenopathies Department, Ramos Mejía Hospital, Buenos Aires, Argentina); Washington Bianchi, Breno Valdetaro Bianchi (Department of

Rheumatology-Santa Casa da Misericórdia do Rio de Janeiro, Rio de Janeiro, Brasil); Ivan Castellví (Hospital de la Santa Creu i Sant Pau, Barcelona, Spain); Massimiliano Limonta (USSD Reumatologia, Ospedali Riuniti di Bergamo, Bergamo, Italy); Doron Rimar (Rheumatology Unit Bnai Zion Medical Center, Haifa, Israel); Maura Couto (Unidade de Reumatologia de Viseu, Centro Hospitalar Tondela-Viseu, Viseu, Portugal); François Spertini (Department of Rheumatology, Clinical Immunology and Allergy, Lausanne, Switzerland); Antonella Marcoccia (Capillaroscopic Unit - Sandro Pertini Hospital, Via Monti Tiburtini, Roma, Italy); Sarah Kahl (Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Innere Medizin/Rheumatologie/Immunologie, Rheumaklinik Bad Bramstedt, Bad Bramstedt, Germany); Vivien Hsu (Rutgers- RWJ Scleroderma Program, Rutgers-RWJ Rheumatology Fellowship Program, New Brunswick, New Jersey, USA); Vincent Poindron (Clinical Immunology Internal Medicine, National Referral Center for Systemic Autoimmune Diseases, Nouvel Hopital Civil 1, Strasbourg, France); Sergey Moiseev, Pavel Novikov (Clinic of Nephrology, Internal and Occupational Diseases. Rossolimo, 11/5, Moscow 119992, Russia); Lorinda Chung (Department of Dermatology Stanford University School of Medicine, Redwood City, California, USA); Tim Schmeiser (Krankenhaus St. Josef, Wuppertal-Elberfeld, Germany); Dominik Majewski (Department of Rheumatology and Internal Medicine Poznan University of Poznań, Poland); Zbigniew Zdrojewski (Department of Internal Medicine, Connective Tissue Diseases and Geriatrics, University Clinical Centre, Medical University of Gdansk, Gdansk, Poland); Julia Martínez-Barrio (Department of Rheumatology, Gregorio Marañón Univeristy Hospital, Hospital General Universitario Gregorio Marañón, Calle Dr Esquerdo 47, 28007 Madrid, Spain); Vera Bernardino (Unidade de Doencas Autoimunes - Hospital Curry Cabral, Centro Hospitalar Lisboa Central Rua Beneficência 8, 1069-166 Lisboa,

Portugal); Gabriela Riemekasten (Universitätsklinik Lübeck, Lübeck, Germany); Yair Levy (Meir Medical Center, Kfar-Saba, Israel); Elena Rezus (Division of Rheumatology & Rehabilitation, University of Medicine and Pharmacy "Grigore T. Popa" Iasi, Rehabilitation Hospital, Iasi, Romania); Omer Nuri Pamuk (Trakya University Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Edirne, Turkey); Piercarlo Sarzi Puttini (University Hospital Luigi Sacco, Milano, Italy); Hadi Poormoghim (Scleroderma Study group, Department of Rheumatology. Firoozgar hospital. Beh afarin street.Tehran. Iran); Ina Kötter (Asklepios Clinic Altona, Medical Department 4, Rheumatology Immunology, Nephrology, Hamburg, Germany); Giovanna Cuomo (UOC Medicina Interna, Università della Campania. Napoli. P.zza Miraglia, 80138 Napoli, Italy); Francis Gaches (Médecine Interne,Centre de Compétence Maladies Lysosomales. Hôpital Joseph Ducuing. 15, rue de Varsovie BP 53160 31027 Toulouse, France); Laura Belloli (S.C. Reumatologia, A.O. Ospedale Niguarda Cà GrandaAddress: P.zza Ospedale Maggiore, 3-20162 Milano, Italy); Petros Sfikakis (Rheumatology Unit, First Propaedeutic and Internal Medicine, Athens University Medical School. Agiou Thoma 17, Goudi, Athens); Daniel Furst (Arthritis Association of Southern California. 5230 Pacific Concourse Dr Suite 100 Los Angeles, USA); Ana-Maria Ramazan (Rheumatology Department, Spitalul Clinic Judetean de Urgenta, "Sf Apostol Andrei". Tomis Bvd No 145, Constanta City, 900591 Romania); Jeska de Vries-Bouwstra (Department of Rheumatology, Leiden University Medical Center, Leiden,The Netherlands).

References

1. Denton CP, Khanna D. Systemic sclerosis. Lancet 2017;390:1685-99.

2. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. *J Rheumatol* 1988;15:202-5.
3. Denton CP. Challenges in systemic sclerosis trial design. *Semin Arthritis Rheum* 2019;49:S3-s7.
4. Iudici M, Bafeta A, Atal I, Ravaud P. Ten Years of Interventional Research in Systemic Sclerosis: A Systematic Mapping of Trial Registries. *Arthritis Care Res (Hoboken)* 2020;72:140-8.
5. Guyatt GH, Haynes RB, Jaeschke RZ, Cook DJ, Green L, Naylor CD, et al. Users' Guides to the Medical Literature: XXV. Evidence-based medicine: principles for applying the Users' Guides to patient care. Evidence-Based Medicine Working Group. *Jama* 2000;284:1290-6.
6. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *Bmj* 2019;366:l4898.
7. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?". *Lancet* 2005;365:82-93.
8. Eggener S. Generalizability of Clinical Trials: Why It Matters for Patients and Public Policy *Eur Urol* 2017;71:515-6.
9. Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. *Jama* 2007;297:1233-40.
10. Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. *Trials* 2015;16:495.
11. Villela R, Yuen SY, Pope JE, Baron M. Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment. *Arthritis Rheum* 2008;59:706-13.
12. <https://clinicaltrials.gov>. [Available from: <https://clinicaltrials.gov>]. Accessed on 28th February 2018.

13. Khanna D, Furst DE, Allanore Y, Bae S, Bodukam V, Clements PJ, et al. Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. *Rheumatology (Oxford)* 2015;54:144-51.

14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976;16:31-41.

15. Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. *Ann Rheum Dis* 2012;71:1355-60.

16. Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. *Ann Rheum Dis* 2007;66:754-63.

17. Sieber S, Cheval B, Orsholits D, Van der Linden BW, Guessous I, Gabriel R, et al. Welfare regimes modify the association of disadvantaged adult-life socioeconomic circumstances with self-rated health in old age. *Int J Epidemiol* 2019;48:1352-1366.

18. Lindsay WA, Murphy MM, Almghairbi DS, Moppett IK. Age, sex, race and ethnicity representativeness of randomised controlled trials in peri-operative medicine. *Anaesthesia* 2020;75:809-815.

19. Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. *JAMA* 2001;286:708-13.

20. McMurdo ME, Roberts H, Parker S, Wyatt N, May H, Goodman C, et al. Improving recruitment of older people to research through good practice. *Age Ageing* 2011;40:659-65.

21. Matucci-Cerinic M, Krieg T, Guillemin L, Schwierin B, Rosenberg D, Cornelisse P, et al. Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. *Ann Rheum Dis* 2016;75:1770-6.

22. Lescoat A, Murphy SL, Roofeh D, Pauling JD, Hughes M, Sandler R, et al. Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. *Journal of Scleroderma and Related Disorders* 2020;6:66-76.

23. Jaeger VK, Tikly M, Xu D, Siegert E, Hachulla E, Airò P, et al. Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. *Rheumatology (Oxford)* 2020;59(7):1684-1694.

Tables

Table 1. Characteristics of SSc patients (n=8046) included in the present study.

Characteristics	n ^a	Overall sample
Age, median (IQR), years	8042	58 (48-67)
Male sex, n, %	8046	1193 (14.8)
Body weight, median (IQR), kilograms	7017	64 (56-74)
Disease characteristics		
dcSSc subset, n, %	5069	1594 (31.4)
Disease duration since first non-Raynaud symptom, median (IQR), years	6952	9 (4-15)
mRSS, median (IQR)	8046	4 (0-10)
Raynaud's phenomenon, n, %	7715	7325 (94.9)
Intestinal symptoms, n, %	7733	1916 (24.8)
Puffy fingers, current, n, %	6484	2308 (35.6)
Current digital ulcers, n, %	6027	883 (14.6)
Pulmonary hypertension by echocardiography, n, %	7732	889 (11.5)
DLCO/SB, median (IQR), % of predicted	5877	69 (55-82)
FVC, median (IQR), % of predicted	6188	97 (81-111)
Renal crisis, ever, n, %	7974	122 (1.5)
Laboratory parameters		
Creatine-kinase elevation (>3 ULN), n, %	6500	494 (7.6)
Anti-centromere positive, n, %	6747	2842 (42.1)
Anti-topoisomerase I positive, n, %	6808	2248 (33.0)
Anti-RNA polymerase III, n, %	4560	205 (4.5)

^a Number of patients with available information for each variable. **IQR**, interquartile range; **mRSS**, modified Rodnan skin score; **SD**, standard deviation; **PAPsys**, systolic pulmonary artery pressure as estimated by echocardiography; **DLCO/sb**, Single breath diffusing capacity for carbon monoxide; **FVC**, forced vital capacity; **ULN**, upper limit of normal.

Table 2. Characteristics of RCTs included in the analysis.

Item and subcategory	RCTs
	N=37
International	12 (32)
Location of studies*	
North America	19 (51)
Europe	16 (43)
Asia	13 (35)
South America	6 (16)
Oceania	3 (8)
Africa	2 (5)
Industry-funded	13 (35)
Type of intervention	
Pharmacologic	32 (86.5)
Non-pharmacologic	5 (13.5)
Study design	
Parallel group	36 (97)
Crossover	1 (3)
Type of comparator	
Placebo	28 (76)
Active (pharmacologic)	5 (14)
Usual care	2 (5)
No intervention	2 (5)
Eligibility criteria	N=575
Mean (SD) number of eligibility criteria per trial	
Demographics	24 (4)
Characteristics of disease	170 (29)
Ethical and administrative	38 (7)
Treatment	81 (14)
Safety	262 (46)
Organ manifestation being evaluated*	
Skin fibrosis	15 (40)
Raynaud's phenomenon/digital ulcers	10 (27)
Interstitial lung disease	5 (13)
Gastrointestinal disease	1 (3)
Pulmonary hypertension	1 (3)
Renal disease	1 (3)
Calcinosis	1 (3)
Other	3 (8)
Sample size	
No. of patients planned to be included or included per study (median, IQR)	60 (32-90)

*Multiple answers were possible. **IQR.** Interquartile range.

Table 3. The proportion of eligible patients per trial from overall sample and from the subgroup of patients with the condition of interest being investigated by each trial.

	% eligible pts (overall sample) N=8046 complete case [worst-best]	% eligible pts (with the condition of interest) complete case [worst-best]
Skin fibrosis		
NCT02551042* (CSL Behring Sclero XIII)	62.3 [20.8-82.6]	67.6 [28.4-88.6]
NCT03068234*	11 [3.0-21.1]	79.0 [41.8-98.6]
NCT03141125*	20.5 [6.6-31.5]	33.2 [12-52.1]
NCT03365869*	14 [5.6-39.8]	32.2 [15.3-80.6]
NCT02921971§	1.2 [0.3-3.7]	19.1 [11.8-45.9]
NCT02453256§ (focuSSced)	5.2 [2.1-8.3]	53.9 [31.8-97.7]
NCT02588625§	11.1 [5.4-31.7]	82.6 [72.7-84.7]
NCT02283762§	1.6 [0.4-4.5]	48.4 [33.3-100]
NCT02503644§ (FASST)	8.0 [0-8.0]	50 [0.8-92]
NCT02161406§ (ASSET)	2 [0.5-4.2]	25.9 [16-49.6]
NCT01785056§	7.5 [6.2-10.6]	56.9 [54.4-77.8]
NCT02349009§	0.2 [0-5.1]	20 [11.1-61.1]
NCT03274076§° (TOFA-SSc)	3.3 [0.8-6.9]	28.3 [17.4-57.4]
NCT01651143§°	4.5 [1.8-7.5]	59.5 [42.1-98.2]
NCT03398837^ (RESOLVE-1)	11.0 [7.8-36.4]	95.0 [50.6-97.3]
All skin fibrosis, median (IQR)	7.5 (2-11)	50 (28.3-67.6)
Interstitial lung disease		
NCT01862926 (RECITAL)	30.0 [20.2-53.0]	76.9 [35.8-95.1]
NCT02370693	1.5 [0.6-49.6]	50 [30.1-98.1]
NCT02896205 (MYILD)	42.3 [9.3-81.1]	68.2 [17.9-96.9]
NCT02597933	10.5 [0-13.2]	33.3 [0.8-38.6]
NCT01933334 (LOTUSS)	7.5 [1.2-12.0]	72.9 [25.5-99.5]

All ILD, median (IQR)	10.5 (4.5-36.1)	68.2 (41.6-74.9)
Raynaud's phenomenon		
NCT03027674	48.3 [46.7-59.2]	49 [47.8-59.9]
NCT01090492	65.8 [21.6-84.8]	74.2 [25.3-96.0]
NCT03058887	18.9 [3.1-48.4]	54.4 [21.4-91.0]
NCT02165111	92.0 [48.3-97.5]	92.9 [49.5-98.8]
NCT02480335	38.4 [35.5-66.1]	99.5 [99.5-99.9]
NCT02370784 (TAMER)	13.9 [7.9-26.6]	100 [0.2-73.2]
NCT02260557	88.7 [47.1-96.0]	89.5 [48.2-97.3]
All Raynaud's, median (IQR)	48.3 (18.9-88.7)	89.5 (54.4-99.5)
Digital ulcers		
NCT02356809	2.4 [0-57.7]	10 [0.1-92.1]
NCT02801305	20.6 [16.5-58.4]	86.4 [86.4-91.8]
NCT02733978	23.9 [19.1-59.5]	100 [100-100]
All digital ulcers, median (IQR)	20.6 (2.4-23.9)	86.4 (10-100)
Pulmonary hypertension		
NCT03053739 (BosSilSS)	30.8 [8.3-65.8]	61.1 [30.3-98.1]
Gastrointestinal		
NCT02302352	44.6 [38.6-51.4]	100 (100-100)
Renal		
NCT02047708 (ZEBRA)	1.1 [0.5-3.3]	83 [81.5-87.0]
Other		
NCT01733056	7.5 [6.2-10.6]	56.9 [54.4-77.8]
NCT01918904 (STS-CALC)	6.3 [1.5-50.0]	30 [29.8-54.8]
NCT02780674	63.7 [31.5-71.3]	64 [33.2-72.4]

* studies on patients with both lcSSc and dcSSc subset; § studies on patients with dcSSc only; ° Safety as primary outcome, mRss as secondary outcome; ^study on dcSSc patients having the American College of Rheumatology Combined Response Index score (CRISS) as primary outcome. RCTs. Randomized controlled trials; **IQR**, interquartile range; **ILD**, interstitial lung disease.

Table 4. Factors associated with the 'never eligible' status in the whole sample of studies included and according to the disease complication tailored by trials.

Factor	All trials		Skin fibrosis		Interstitial lung disease		Raynaud's phenomenon	
	Univariable OR (95% CI)	Multivariable OR (95% CI)	Univariable OR (95% CI)	Multivariable OR (95% CI)	Univariable OR (95% CI)	Multivariable OR (95% CI)	Univariable OR (95% CI)	Multivariable OR (95% CI)
Age	1.01 (1.00-1.02)*	1.02 (1.00-1.04)**	1.03 (1.02-1.03)*	1.02 (1.01-1.03)**	1.01 (1.00-1.02)**	1.01 (1.00-1.02)*	1.01 (1.00-1.02)**	1.02 (1.01-1.04)**
Male	0.83 (0.66-1.04)		0.54 (0.47-0.61)**		0.86 (0.75-0.99)**		0.83 (0.69-0.99)**	
Time from first non-Raynaud	0.99 (0.98-1.01)		1.07 (1.06-1.08)**	1.03 (1.02-1.04)**	1.01 (1.00-1.02)**		1.02 (0.99-1.01)	0.98 (0.96-0.99)*
lcSSc	4.03 (2.92-5.71)**		5.41 (4.76-6.17)**	3.55 (2.59-4.91)**	1.48 (1.30-1.68)**		1.95 (1.59-2.41)**	2.04 (1.18-2.64)**
Raynaud's phenomenon	0.20 (0.15-0.25)**	0.30 (0.13-0.80)**	0.65 (0.51-0.82)**		0.53 (0.40-0.70)**		-	
Current digital ulcers	0.12 (0.06-0.23)**		0.69 (0.51-0.93)**		0.67 (0.48-0.93)*		0.67 (0.48-0.95)**	
mRSS	0.90 (0.89-0.92)**	0.91 (0.86-0.97)**	0.93 (0.92-0.94)**	0.94 (0.92-0.96)**	0.98 (0.97-0.98)**		0.97 (0.96-0.98)**	
Creatin kinase elevation	0.93 (0.64-1.30)		0.64 (0.53-0.77)**		1.41 (1.13-1.77)*	2.02 (1.36-3.05)**	1.01 (0.77-1.31)	
Renal crisis	1.12 (0.58-1.96)		0.84 (0.58-1.21)		1.22 (0.80-1.93)		1.83 (1.18-2.74)*	3.31 (1.22-8.17)*
Dyspnea any stage	0.90 (0.79-1.02)		1.00 (0.94-1.07)		0.87 (0.81-0.94)**		1.02 (0.93-1.12)	
Left ventricular EF	1.01 (1.00-1.03)*		1.00 (0.99-1.01)		1.01 (1.00-1.02)**		1.01 (1.00-1.02)**	
Conduction blocks	0.95 (0.70-1.26)		1.06 (0.91-1.24)		0.90 (0.77-1.07)		1.13 (0.91-1.39)	
Pulmonary hypertension	1.04 (0.79-1.34)		1.99 (1.69-2.34)**	2.49 (1.69-3.71)**	1.09 (0.93-1.29)		1.41 (1.17-1.70)**	1.66 (1.02-2.65)°
Anti-Scl70 positive	0.58 (0.47-0.72)**		0.44 (0.39-0.48)**	0.72 (0.53-0.98)*	0.48 (0.43-0.54)**	0.56 (0.43-0.74)**	0.71 (0.61-0.83)**	
Anti-centromere positive	1.68 (1.41-2.01)**		2.40 (2.16-2.67)**		1.94 (1.73-2.17)**	1.45 (1.12-1.89)**	1.44 (1.26-1.66)**	
FVC<80% of predicted	0.72 (0.56-0.92)*		0.69 (0.61-0.78)*		0.74 (0.65-0.84)**		0.92 (0.77-1.10)	
DLCO<% of predicted	0.59 (0.48-0.72)**		0.80 (0.71-0.90)*		0.80 (0.71-0.91)**		0.80 (0.71-0.91)**	
Active disease	0.76 (0.71-0.81)**		0.80 (0.78-0.83)**		0.90 (0.88-0.93)**		0.94 (0.91-0.98)**	


lcSSc. limited cutaneous SSc; mRSS. Modified Rodnan skin score; EF. Ejection fraction; FVC. Forced vital capacity; DLCO. Diffusing lung capacity for carbon monoxide. **p<0.001, *p<0.05, °0.

Table 5. Proportion of ‘never eligible’ patients according to the country.

N of ‘never eligible’/total number of patients (%)					
Country	All studies	Skin fibrosis	ILD	Raynaud’s phenomenon	Digital ulcers
Belgium	13/281 (4.6)	146 (51.9)	224 (79.7)	22 (7.8)	245 (87.2)
Croatia	43/165 (26.1)	123 (74.5)	149 (90.3)	74 (44.8)	131 (79.4)
Denmark	5/114 (4.4)	98 (85.9)	102 (89.4)	8 (7.0)	82 (71.9)
France	109/823 (13.2)	534 (64.9)	695 (84.4)	166 (20.2)	690 (83.8)
Germany	92/1267 (7.3)	839 (66.2)	920 (72.6)	145 (11.4)	988 (78.0)
Hungary	3/215 (1.4)	98 (45.5)	126 (58.6)	3 (1.4)	184 (85.6)
Israel	21/167 (12.6)	143 (85.6)	261 (96.4)	43 (25.7)	116 (69.4)
Italy	153/2031 (7.5)	1369 (67.4)	1365 (67.2)	272 (13.4)	1671 (82.3)
Poland	22/138 (15.9)	95 (68.8)	133 (96.3)	41 (29.7)	114 (82.6)
Romania	8/322 (2.5)	130 (40.4)	216 (67.1)	27 (8.4)	226 (70.2)
Russia	4/141 (2.8)	59 (41.8)	38 (26.9)	5 (3.5)	98 (69.5)
Spain	108/619 (17.4)	512 (82.7)	584 (94.3)	144 (23.2)	555 (89.7)
Switzerland	23/545 (4.2)	313 (57.4)	281 (51.5)	47 (8.6)	454 (83.3)
Turkey	13/132 (9.8)	74 (56.1)	101 (76.5)	25 (18.9)	104 (78.8)
UK	1/282 (0.35)	161 (57.1)	200 (70.9)	4 (1.4)	219 (77.6)

ILD. interstitial lung disease.

Figure 1. Proportion of 'never eligible' patients across countries for each trial category.



Legend. ILD, interstitial lung disease.